// App-Quantinova.ai

: Comparison of hyperphagia and problem behaviors in participants with prader-willi syndrome (PWS) receiving diazoxide choline extended-release (DCCR) with matched participants in PATH for PWS (PfPWS)

Researchers

Presenter

  • Evelien Gevers

Principal Investigators

  • Jennifer Miller

  • Eric Felner

  • Tony Goldstone

  • Nicola Bridges

  • Jack Yanovski

  • Lynne Bird

  • Merlin Butler

  • Kathryn Obrynba

  • Melissa Lah

  • Ashley Shoemaker

  • Jorge Mejia-Corletto

  • David Stevenson

  • John Wilding

  • Virginia Kimonis

  • Jennifer Abuzzahab

  • Laura Konczal

  • Verghese Mathew

  • Neil Cowen

  • Michael Woloschak

  • Anish Bhatnagar

Medical Centers

  • Queen Mary University of London, Barts Health Trust, London, United Kingdom

  • Foundation for Prader-Willi Research, Walnut, United States

  • PATH for PWS Investigators

  • Gastroenterology, University of Florida, Gainesville, Florida, United States

  • Emory Children’s Center, Druid Hills, United States

  • Hammersmith Hospital NHS Trust, London, United Kingdom

  • Chelsea and Westminster Hospital, London, United Kingdom

  • National Institute of Health, Bethesda, MD, United States

  • Rady Children's Hospital, San Diego, United States

  • Kansas University Medical Center, Kansas City, KS

  • The Research Institute at Nationwide Children's Hospital, Columbus, OH

  • Indiana University School of Medicine, Indianapolis, IN

  • Vanderbilt University, Nashville, Tennessee, United States

  • NYU Winthrop Hospital, Mineola, NY, United States

  • NYU Langone Hospital-Long Island, Pediatrics, Division of Pediatric Endocrinology, Mineola,

  • VA Palo Alto HCS/ Stanford University, Palo Alto, California, United States

  • University of Liverpool, Liverpool, United Kingdom

  • University of California Irvine,Irvine, United States

  • Children’s Minnesota, Saint Paul, United States

  • 7Cleveland VA Medical Center Cleveland OH United States

  • Hull & East Yorkshire NHS Trust, Hull, United Kingdom

  • Soleno Therapeutics, Inc., Redwood City, United States

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Prader-willi syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Diazoxide

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • NCT03440814

  • NCT03714373

  • NCT03718416

Sponsors

  • Soleno Therapeutics and a matched sub-cohort from PfPWS

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved